Vault-13

DEERFIELD MANAGEMENT COMPANY, L.P.

New York, NY · CIK 1009258 · 13F filing filed 2021-08-16

SEC-registered investment adviser since 2012 · limited partnership

As an employer

Where they work

people there (dot area)number not reportedmain officeHover or tap a dot. Australian and UK companies are placed at their business or registered address, with their staff across the whole country.

Offices

From Form ADV: the main office and the other offices where it does advisory work (at most the 25 largest), with the people doing investment work at each. “About” is worked out: the firm's investment staff less its other offices. Each city links to the other managers there.

CityCountryPeople
New York, NY (main office)United States United Statesabout 86
Parsippany, NJUnited States United States3

US visa salary filings

Job titleFilingsMedianRange
AnalystNew York, NY 2 $140,000
Data EngineerNew York, NY 1 $210,000
Senior Director, Business IntelligenceNew York, NY 1 $195,000
Director, Business IntelligenceNew York, NY 1 $180,000
Market Research AssociateNew York, NY 1 $80,000

Source: US Department of Labor, Labor Condition Application disclosure data (certified, full-time, yearly equivalent). These are the salaries the employer committed to pay the visa roles it filed for, at least the prevailing wage for the job and place; they are not the pay of all its staff. Filed by: Deerfield Management Company, L.P..

Map: places from GeoNames (CC BY 4.0), outlines from Natural Earth.

$5.6bn reported value +18.3% vs Q1 2021
143positions
33.0%in top 10
37 new 31 added 13 reduced 27 sold out vs Q1 2021

This report includes the holdings of 1 other manager that shares the investment decisions:

Shares in two reports are counted once in each security's totals.

Holdings, Q2 2021

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#SecurityTickerShares Value% of portfolioChangeShares change
1 VIATRIS INC COM VTRS VTRS 18,824,000 $269.0m4.78% 4.78% AddedShares held: Q3 2020 0, Q4 2020 15.7m, Q1 2021 17.2m, Q2 2021 18.8m +1.6m +1,600,000 9.3%
2 SINGULAR GENOMICS SYSTEMS IN COM COM 9,112,019 $250.4m4.45% 4.45% NewShares held: Q3 2020 0, Q4 2020 0, Q1 2021 0, Q2 2021 9.1m
3 INVITAE CORP NOTE 2.000% 9/0 · principal NVTA 2 09.01.24 · principal NVTA 2 09.01.24 163,385,000 $221.7m3.94% 3.94% UnchangedPrincipal held: Q3 2020 163.4m, Q4 2020 0, Q1 2021 163.4m, Q2 2021 163.4m
4 CAREMAX INC COM CL A COM CL A 16,778,750 $216.4m3.84% 3.84% NewShares held: Q3 2020 0, Q4 2020 0, Q1 2021 0, Q2 2021 16.8m
5 ADAPTHEALTH CORP COMMON STOCK AHCO AHCO 7,353,792 $201.6m3.58% 3.58% AddedShares held: Q3 2020 1.7m, Q4 2020 1.8m, Q1 2021 2.3m, Q2 2021 7.4m +5.1m +5,075,921 222.8%
6 AERIE PHARMACEUTICALS INC NOTE 1.500%10/0 · principal AERI 1.5 10.01.24 · principal AERI 1.5 10.01.24 157,390,000 $156.6m2.78% 2.78% AddedPrincipal held: Q3 2020 149.6m, Q4 2020 0, Q1 2021 149.6m, Q2 2021 157.4m +7.8m +7,790,000 5.2%
7 GLAUKOS CORP NOTE 2.750% 6/1 · principal GKOS 2.75 06.15.27 · principal GKOS 2.75 06.15.27 90,000,000 $153.5m2.73% 2.73% NewPrincipal held: Q3 2020 0, Q4 2020 0, Q1 2021 0, Q2 2021 90.0m
8 NATERA INC NOTE 2.250% 5/0 · principal NTRA 2.25 05.01.27 · principal NTRA 2.25 05.01.27 45,000,000 $136.3m2.42% 2.42% NewPrincipal held: Q3 2020 0, Q4 2020 0, Q1 2021 0, Q2 2021 45.0m
9 BRIDGEBIO PHARMA INC NOTE 2.500% 3/1 · principal BBIO 2.5 03.15.27 · principal BBIO 2.5 03.15.27 80,000,000 $131.2m2.33% 2.33% UnchangedPrincipal held: Q3 2020 0, Q4 2020 0, Q1 2021 80.0m, Q2 2021 80.0m
10 ORGANOGENESIS HLDGS INC COM ORGO ORGO 7,222,127 $120.0m2.13% 2.13% AddedShares held: Q3 2020 0, Q4 2020 0, Q1 2021 3.0m, Q2 2021 7.2m +4.2m +4,226,489 141.1%
11 ENVISTA HOLDINGS CORPORATION NOTE 2.375% 6/0 · principal NVST 2.375 06.01.25 · principal NVST 2.375 06.01.25 52,500,000 $112.0m1.99% 1.99% NewPrincipal held: Q3 2020 0, Q4 2020 0, Q1 2021 0, Q2 2021 52.5m
12 NUVASIVE INC NOTE 1.000% 6/0 · principal GMED 1 06.01.23 · principal GMED 1 06.01.23 96,966,000 $101.3m1.80% 1.80% NewPrincipal held: Q3 2020 0, Q4 2020 0, Q1 2021 0, Q2 2021 97.0m
13 EDGEWISE THERAPEUTICS INC COM EWTX EWTX 3,933,137 $83.9m1.49% 1.49% UnchangedShares held: Q3 2020 0, Q4 2020 0, Q1 2021 3.9m, Q2 2021 3.9m
14 PULMONX CORP COM LUNG LUNG 1,800,887 $79.5m1.41% 1.41% AddedShares held: Q3 2020 0, Q4 2020 463.5k, Q1 2021 937.0k, Q2 2021 1.8m +863.9k +863,855 92.2%
15 INSULET CORP NOTE 0.375% 9/0 · principal PODD 0.375 09.01.26 · principal PODD 0.375 09.01.26 57,581,000 $78.2m1.39% 1.39% UnchangedPrincipal held: Q3 2020 0, Q4 2020 0, Q1 2021 57.6m, Q2 2021 57.6m
16 APELLIS PHARMACEUTICALS INC NOTE 3.500% 9/1 · principal APLS 3.5 09.15.26 · principal APLS 3.5 09.15.26 41,825,000 $77.8m1.38% 1.38% AddedPrincipal held: Q3 2020 64.8m, Q4 2020 0, Q1 2021 21.8m, Q2 2021 41.8m +20.0m +20,000,000 91.6%
17 ACUTUS MED INC COM AFIB AFIB 4,341,799 $73.7m1.31% 1.31% UnchangedShares held: Q3 2020 4.3m, Q4 2020 4.3m, Q1 2021 4.3m, Q2 2021 4.3m
18 CENTENE CORP DEL COM CNC CNC 995,000 $72.6m1.29% 1.29% ReducedShares held: Q3 2020 1.8m, Q4 2020 2.4m, Q1 2021 2.0m, Q2 2021 995.0k -990.6k -990,619 -49.9%
19 NEUROCRINE BIOSCIENCES INC COM NBIX NBIX 725,000 $70.6m1.25% 1.25% UnchangedShares held: Q3 2020 0, Q4 2020 0, Q1 2021 725.0k, Q2 2021 725.0k
20 PACIRA BIOSCIENCES INC COM PCRX PCRX 1,147,000 $69.6m1.24% 1.24% ReducedShares held: Q3 2020 1.2m, Q4 2020 1.0m, Q1 2021 1.2m, Q2 2021 1.1m -18.0k -17,973 -1.5%
21 PROTAGONIST THERAPEUTICS INC COM PTGX PTGX 1,362,790 $61.2m1.09% 1.09% AddedShares held: Q3 2020 1.2m, Q4 2020 1.4m, Q1 2021 1.3m, Q2 2021 1.4m +104.0k +104,000 8.3%
22 MIRUM PHARMACEUTICALS INC COM MIRM MIRM 3,448,912 $59.6m1.06% 1.06% UnchangedShares held: Q3 2020 3.4m, Q4 2020 3.4m, Q1 2021 3.4m, Q2 2021 3.4m
23 MOLINA HEALTHCARE INC COM MOH MOH 231,776 $58.7m1.04% 1.04% UnchangedShares held: Q3 2020 153.0k, Q4 2020 125.0k, Q1 2021 231.8k, Q2 2021 231.8k
24 LARIMAR THERAPEUTICS INC COM LRMR LRMR 5,830,249 $57.3m1.02% 1.02% AddedShares held: Q3 2020 5.1m, Q4 2020 5.1m, Q1 2021 5.1m, Q2 2021 5.8m +685.7k +685,710 13.3%
25 INSMED INC NOTE 0.750% 6/0 · principal INSM 0.75 06.01.28 · principal INSM 0.75 06.01.28 50,000,000 $55.5m0.99% 0.99% NewPrincipal held: Q3 2020 0, Q4 2020 0, Q1 2021 0, Q2 2021 50.0m
26 SILK RD MED INC COM SILK SILK 1,138,525 $54.5m0.97% 0.97% AddedShares held: Q3 2020 0, Q4 2020 113.0k, Q1 2021 488.5k, Q2 2021 1.1m +650.0k +649,980 133.0%
27 ZIMMER BIOMET HOLDINGS INC COM ZBH ZBH 338,000 $54.4m0.97% 0.97% ReducedShares held: Q3 2020 0, Q4 2020 95.0k, Q1 2021 357.0k, Q2 2021 338.0k -19.0k -19,000 -5.3%
28 CONSTELLATION PHARMCETICLS I COM CNST CNST 1,601,427 $54.1m0.96% 0.96% ReducedShares held: Q3 2020 1.0m, Q4 2020 1.5m, Q1 2021 1.7m, Q2 2021 1.6m -107.5k -107,530 -6.3%
29 INSMED INC NOTE 1.750% 1/1 · principal INSM 1.75 01.15.25 · principal INSM 1.75 01.15.25 50,000,000 $52.5m0.93% 0.93% ReducedPrincipal held: Q3 2020 61.0m, Q4 2020 0, Q1 2021 61.0m, Q2 2021 50.0m -11.0m -11,000,000 -18.0%
30 QUIDEL CORP COM QDEL QDEL 409,219 $52.4m0.93% 0.93% NewShares held: Q3 2020 130.5k, Q4 2020 220.0k, Q1 2021 0, Q2 2021 409.2k
31 ALPHATEC HLDGS INC COM NEW ATEC ATEC 3,402,384 $52.1m0.93% 0.93% AddedShares held: Q3 2020 0, Q4 2020 2.0m, Q1 2021 3.2m, Q2 2021 3.4m +200.5k +200,468 6.3%
32 INTERCEPT PHARMACEUTICALS IN NOTE 3.250% 7/0 · principal ICPT 3.25 07.01.23 · principal ICPT 3.25 07.01.23 57,791,000 $51.9m0.92% 0.92% UnchangedPrincipal held: Q3 2020 57.8m, Q4 2020 0, Q1 2021 57.8m, Q2 2021 57.8m
33 KALVISTA PHARMACEUTICALS INC COM KALV KALV 2,163,554 $51.8m0.92% 0.92% AddedShares held: Q3 2020 0, Q4 2020 0, Q1 2021 1.0m, Q2 2021 2.2m +1.1m +1,143,549 112.1%
34 DFP HEALTHCARE ACQUISITNS CO COM CL A COM CL A 5,000,000 $49.8m0.88% 0.88% ReducedShares held: Q3 2020 0, Q4 2020 5.5m, Q1 2021 10.5m, Q2 2021 5.0m -5.5m -5,460,000 -52.2%
35 REVOLUTION MEDICINES INC COM RVMD RVMD 1,565,712 $49.7m0.88% 0.88% AddedShares held: Q3 2020 1.8m, Q4 2020 1.4m, Q1 2021 1.4m, Q2 2021 1.6m +129.0k +129,000 9.0%
36 DECIPHERA PHARMACEUTICALS IN COM DCPH DCPH 1,343,560 $49.2m0.87% 0.87% AddedShares held: Q3 2020 528.6k, Q4 2020 528.6k, Q1 2021 528.6k, Q2 2021 1.3m +815.0k +814,975 154.2%
37 CLOVIS ONCOLOGY INC NOTE 2.500% 9/1 · principal CLVS 2.5 09.15.21 · principal CLVS 2.5 09.15.21 49,064,000 $47.8m0.85% 0.85% UnchangedPrincipal held: Q3 2020 49.1m, Q4 2020 0, Q1 2021 49.1m, Q2 2021 49.1m
38 SPRINGWORKS THERAPEUTICS INC COM SWTX SWTX 558,574 $46.0m0.82% 0.82% UnchangedShares held: Q3 2020 1.2m, Q4 2020 1.4m, Q1 2021 558.6k, Q2 2021 558.6k
39 TABULA RASA HEALTHCARE INC NOTE 1.750% 2/1 · principal TRHC 1.75 02.15.26 · principal TRHC 1.75 02.15.26 45,000,000 $45.6m0.81% 0.81% UnchangedPrincipal held: Q3 2020 0, Q4 2020 0, Q1 2021 45.0m, Q2 2021 45.0m
40 GALAPAGOS NV SPON ADR LKFT LKFT 657,005 $45.3m0.80% 0.80% NewShares held: Q3 2020 0, Q4 2020 0, Q1 2021 0, Q2 2021 657.0k
41 BIOCRYST PHARMACEUTICALS INC COM BCRX BCRX 2,835,000 $44.8m0.80% 0.80% AddedShares held: Q3 2020 4.5m, Q4 2020 5.8m, Q1 2021 2.6m, Q2 2021 2.8m +229.6k +229,620 8.8%
42 NOVAVAX INC NOTE 3.750% 2/0 · principal NVAX 3.75 02.01.23 · principal NVAX 3.75 02.01.23 25,000,000 $44.6m0.79% 0.79% UnchangedPrincipal held: Q3 2020 0, Q4 2020 0, Q1 2021 25.0m, Q2 2021 25.0m
43 WEREWOLF THERAPEUTICS INC COM HOWL HOWL 2,552,787 $44.5m0.79% 0.79% NewShares held: Q3 2020 0, Q4 2020 0, Q1 2021 0, Q2 2021 2.6m
44 APRIA INC COM COM 1,572,892 $44.0m0.78% 0.78% AddedShares held: Q3 2020 0, Q4 2020 0, Q1 2021 1.2m, Q2 2021 1.6m +372.9k +372,892 31.1%
45 ONCORUS INC COM COM 3,148,977 $43.5m0.77% 0.77% UnchangedShares held: Q3 2020 0, Q4 2020 2.8m, Q1 2021 3.1m, Q2 2021 3.1m
46 REATA PHARMACEUTICALS INC CL A RETA RETA 300,000 $42.5m0.75% 0.75% ReducedShares held: Q3 2020 448.0k, Q4 2020 320.0k, Q1 2021 420.0k, Q2 2021 300.0k -120.0k -120,000 -28.6%
47 OWENS & MINOR INC NEW COM ACH ACH 996,500 $42.2m0.75% 0.75% ReducedShares held: Q3 2020 1.5m, Q4 2020 1.1m, Q1 2021 1.5m, Q2 2021 996.5k -552.5k -552,500 -35.7%
48 NUVASIVE INC NOTE 0.375% 3/1 · principal GMED 0.375 03.15.25 · principal GMED 0.375 03.15.25 40,000,000 $39.6m0.70% 0.70% UnchangedPrincipal held: Q3 2020 0, Q4 2020 0, Q1 2021 40.0m, Q2 2021 40.0m
49 RHYTHM PHARMACEUTICALS INC COM RYTM RYTM 1,989,625 $39.0m0.69% 0.69% UnchangedShares held: Q3 2020 1.9m, Q4 2020 2.7m, Q1 2021 2.0m, Q2 2021 2.0m
50 KURA ONCOLOGY INC COM KURA KURA 1,794,000 $37.4m0.66% 0.66% NewShares held: Q3 2020 0, Q4 2020 0, Q1 2021 0, Q2 2021 1.8m
51 INOZYME PHARMA INC COM COM 2,178,985 $37.1m0.66% 0.66% AddedShares held: Q3 2020 1.2m, Q4 2020 1.2m, Q1 2021 2.0m, Q2 2021 2.2m +215.0k +214,985 10.9%
52 IVERIC BIO INC COM OPHT OPHT 5,767,409 $36.4m0.65% 0.65% UnchangedShares held: Q3 2020 5.8m, Q4 2020 5.8m, Q1 2021 5.8m, Q2 2021 5.8m
53 PUMA BIOTECHNOLOGY INC COM PBYI PBYI 3,769,795 $34.6m0.61% 0.61% UnchangedShares held: Q3 2020 2.8m, Q4 2020 4.0m, Q1 2021 3.8m, Q2 2021 3.8m
54 BIODELIVERY SCIENCES INTL IN COM BDSI BDSI 9,530,000 $34.1m0.61% 0.61% UnchangedShares held: Q3 2020 7.6m, Q4 2020 9.5m, Q1 2021 9.5m, Q2 2021 9.5m
55 NUVATION BIO INC COM CL A NUVB NUVB 3,577,233 $33.3m0.59% 0.59% AddedShares held: Q3 2020 0, Q4 2020 0, Q1 2021 3.0m, Q2 2021 3.6m +577.2k +577,233 19.2%
56 WAVE LIFE SCIENCES LTD SHS 96663EUR 96663EUR 4,829,069 $32.2m0.57% 0.57% AddedShares held: Q3 2020 0, Q4 2020 0, Q1 2021 3.5m, Q2 2021 4.8m +1.3m +1,326,099 37.9%
57 MERIDIAN BIOSCIENCE INC COM VIVO VIVO 1,424,274 $31.6m0.56% 0.56% AddedShares held: Q3 2020 1.5m, Q4 2020 2.2m, Q1 2021 889.3k, Q2 2021 1.4m +535.0k +535,005 60.2%
58 ORCHARD THERAPEUTICS PLC ADS ORTX ORTX 6,949,416 $30.5m0.54% 0.54% UnchangedShares held: Q3 2020 6.9m, Q4 2020 6.9m, Q1 2021 6.9m, Q2 2021 6.9m
59 ARDELYX INC COM ARDX ARDX 3,811,554 $28.9m0.51% 0.51% AddedShares held: Q3 2020 2.6m, Q4 2020 2.6m, Q1 2021 2.6m, Q2 2021 3.8m +1.2m +1,250,000 48.8%
60 TERNS PHARMACEUTICALS INC COM COM 2,345,959 $28.8m0.51% 0.51% UnchangedShares held: Q3 2020 0, Q4 2020 0, Q1 2021 2.3m, Q2 2021 2.3m
61 HEALTH CATALYST INC NOTE 2.500% 4/1 · principal HCAT 2.5 04.15.25 · principal HCAT 2.5 04.15.25 15,000,000 $28.7m0.51% 0.51% NewPrincipal held: Q3 2020 0, Q4 2020 0, Q1 2021 0, Q2 2021 15.0m
62 GRAYBUG VISION INC COM SHS COM SHS 5,281,713 $28.7m0.51% 0.51% UnchangedShares held: Q3 2020 5.3m, Q4 2020 5.3m, Q1 2021 5.3m, Q2 2021 5.3m
63 XERIS PHARMACEUTICALS INC NOTE 5.000% 7/1 · principal XERS 5 07.15.25 · principal XERS 5 07.15.25 18,000,000 $28.5m0.51% 0.51% UnchangedPrincipal held: Q3 2020 18.0m, Q4 2020 18.0m, Q1 2021 18.0m, Q2 2021 18.0m
64 AMICUS THERAPEUTICS INC COM FOLD FOLD 2,941,492 $28.4m0.50% 0.50% AddedShares held: Q3 2020 0, Q4 2020 0, Q1 2021 2.7m, Q2 2021 2.9m +243.0k +242,995 9.0%
65 ITAMAR MED LTD SPONSORED ADS ITMR ITMR 1,193,803 $28.1m0.50% 0.50% UnchangedShares held: Q3 2020 499.1k, Q4 2020 793.8k, Q1 2021 1.2m, Q2 2021 1.2m
66 GRAPHITE BIO INC COM GRPH GRPH 906,308 $27.9m0.49% 0.49% NewShares held: Q3 2020 0, Q4 2020 0, Q1 2021 0, Q2 2021 906.3k
67 ACCELERON PHARMA INC COM XLRN XLRN 219,500 $27.5m0.49% 0.49% UnchangedShares held: Q3 2020 421.6k, Q4 2020 421.6k, Q1 2021 219.5k, Q2 2021 219.5k
68 PMV PHARMACEUTICALS INC COM PMVP PMVP 804,000 $27.5m0.49% 0.49% AddedShares held: Q3 2020 50.0k, Q4 2020 187.2k, Q1 2021 423.7k, Q2 2021 804.0k +380.3k +380,320 89.8%
69 CULLINAN THERAPEUTICS INC COM CGEM CGEM 1,044,000 $26.9m0.48% 0.48% NewShares held: Q3 2020 0, Q4 2020 0, Q1 2021 0, Q2 2021 1.0m
70 XERIS PHARMACEUTICALS INC COM COM 6,553,398 $26.7m0.47% 0.47% UnchangedShares held: Q3 2020 0, Q4 2020 0, Q1 2021 6.6m, Q2 2021 6.6m
71 FATE THERAPEUTICS INC COM FATE FATE 304,000 $26.4m0.47% 0.47% UnchangedShares held: Q3 2020 668.1k, Q4 2020 0, Q1 2021 304.0k, Q2 2021 304.0k
72 BROOKDALE SR LIVING INC COM BKD BKD 3,298,000 $26.1m0.46% 0.46% ReducedShares held: Q3 2020 17.7m, Q4 2020 11.0m, Q1 2021 7.5m, Q2 2021 3.3m -4.2m -4,192,845 -56.0%
73 BLUEPRINT MEDICINES CORP COM BPMC BPMC 281,754 $24.8m0.44% 0.44% AddedShares held: Q3 2020 405.4k, Q4 2020 0, Q1 2021 209.0k, Q2 2021 281.8k +72.8k +72,754 34.8%
74 AVEANNA HEALTHCARE HLDGS INC COM AVAH AVAH 2,000,000 $24.7m0.44% 0.44% NewShares held: Q3 2020 0, Q4 2020 0, Q1 2021 0, Q2 2021 2.0m
75 CYTOKINETICS INC COM NEW CYTK CYTK 1,238,083 $24.5m0.44% 0.44% ReducedShares held: Q3 2020 0, Q4 2020 2.5m, Q1 2021 2.6m, Q2 2021 1.2m -1.3m -1,322,917 -51.7%
76 BRIGHT HEALTH GROUP INC COM COM 1,400,000 $24.0m0.43% 0.43% NewShares held: Q3 2020 0, Q4 2020 0, Q1 2021 0, Q2 2021 1.4m
77 KINNATE BIOPHARMA INC COM KNTE KNTE 1,020,000 $23.7m0.42% 0.42% AddedShares held: Q3 2020 0, Q4 2020 345.0k, Q1 2021 345.0k, Q2 2021 1.0m +675.0k +675,000 195.7%
78 SPRUCE BIOSCIENCES INC COM COM 2,046,958 $22.9m0.41% 0.41% NewShares held: Q3 2020 0, Q4 2020 0, Q1 2021 0, Q2 2021 2.0m
79 ALECTOR INC COM ALEC ALEC 1,055,192 $22.0m0.39% 0.39% UnchangedShares held: Q3 2020 1.5m, Q4 2020 1.1m, Q1 2021 1.1m, Q2 2021 1.1m
80 INSTIL BIO INC COM COM 1,115,739 $21.6m0.38% 0.38% UnchangedShares held: Q3 2020 0, Q4 2020 0, Q1 2021 1.1m, Q2 2021 1.1m
81 MONTES ARCHIMEDES ACQUISITIO UNIT 09/30/2025 UNIT 09/30/2025 2,000,000 $21.3m0.38% 0.38% NewShares held: Q3 2020 0, Q4 2020 0, Q1 2021 0, Q2 2021 2.0m
82 PROFOUND MED CORP COM NEW PROF PROF 1,297,797 $21.2m0.38% 0.38% UnchangedShares held: Q3 2020 695.0k, Q4 2020 695.0k, Q1 2021 1.3m, Q2 2021 1.3m
83 NEVRO CORP NOTE 2.750% 4/0 · principal NVRO 2.75 04.01.25 · principal NVRO 2.75 04.01.25 12,000,000 $20.9m0.37% 0.37% UnchangedPrincipal held: Q3 2020 12.0m, Q4 2020 12.0m, Q1 2021 12.0m, Q2 2021 12.0m
84 OUTSET MED INC COM OM OM 400,622 $20.0m0.36% 0.36% NewShares held: Q3 2020 125.0k, Q4 2020 175.0k, Q1 2021 0, Q2 2021 400.6k
85 PHARVARIS N V COM PHVS PHVS 1,032,757 $19.2m0.34% 0.34% UnchangedShares held: Q3 2020 0, Q4 2020 0, Q1 2021 1.0m, Q2 2021 1.0m
86 DAY ONE BIOPHARMACEUTICALS I COM COM 818,980 $18.6m0.33% 0.33% NewShares held: Q3 2020 0, Q4 2020 0, Q1 2021 0, Q2 2021 819.0k
87 STEREOTAXIS INC COM NEW STXS STXS 1,843,000 $17.8m0.32% 0.32% NewShares held: Q3 2020 0, Q4 2020 0, Q1 2021 0, Q2 2021 1.8m
88 JANUX THERAPEUTICS INC COM JANX JANX 700,000 $17.5m0.31% 0.31% NewShares held: Q3 2020 0, Q4 2020 0, Q1 2021 0, Q2 2021 700.0k
89 QUANTUM SI INC COM CL A QSI QSI 1,400,000 $17.2m0.30% 0.30% NewShares held: Q3 2020 0, Q4 2020 0, Q1 2021 0, Q2 2021 1.4m
90 DYNE THERAPEUTICS INC COM DYN DYN 787,000 $16.6m0.29% 0.29% AddedShares held: Q3 2020 411.3k, Q4 2020 570.0k, Q1 2021 686.0k, Q2 2021 787.0k +101.0k +101,000 14.7%
91 AEROVATE THERAPEUTICS INC COM COM 714,285 $16.3m0.29% 0.29% NewShares held: Q3 2020 0, Q4 2020 0, Q1 2021 0, Q2 2021 714.3k
92 PTC THERAPEUTICS INC NOTE 3.000% 8/1 · principal PTCT 3 08.15.22 · principal PTCT 3 08.15.22 14,527,000 $15.6m0.28% 0.28% UnchangedPrincipal held: Q3 2020 14.5m, Q4 2020 14.5m, Q1 2021 14.5m, Q2 2021 14.5m
93 BLUEBIRD BIO INC COM COM 480,300 $15.4m0.27% 0.27% UnchangedShares held: Q3 2020 0, Q4 2020 0, Q1 2021 480.3k, Q2 2021 480.3k
94 CHIMERIX INC COM CMRX CMRX 1,816,221 $14.5m0.26% 0.26% UnchangedShares held: Q3 2020 0, Q4 2020 0, Q1 2021 1.8m, Q2 2021 1.8m
95 IMMUNOCORE HLDGS PLC ADS IMCR IMCR 360,966 $14.1m0.25% 0.25% AddedShares held: Q3 2020 0, Q4 2020 0, Q1 2021 171.9k, Q2 2021 361.0k +189.1k +189,058 110.0%
96 MEDAVAIL HOLDINGS INC COM MYOS MYOS 1,142,552 $14.0m0.25% 0.25% UnchangedShares held: Q3 2020 0, Q4 2020 1.1m, Q1 2021 1.1m, Q2 2021 1.1m
97 AVIDITY BIOSCIENCES INC COM RNA RNA 560,132 $13.8m0.25% 0.25% AddedShares held: Q3 2020 474.2k, Q4 2020 454.0k, Q1 2021 454.0k, Q2 2021 560.1k +106.2k +106,159 23.4%
98 BIOVENTUS INC COM CL A BVS BVS 778,567 $13.7m0.24% 0.24% ReducedShares held: Q3 2020 0, Q4 2020 0, Q1 2021 957.0k, Q2 2021 778.6k -178.4k -178,433 -18.6%
99 PRIVIA HEALTH GROUP INC COM PRVA PRVA 300,000 $13.3m0.24% 0.24% NewShares held: Q3 2020 0, Q4 2020 0, Q1 2021 0, Q2 2021 300.0k
100 AERIE PHARMACEUTICALS INC COM AERI AERI 825,937 $13.2m0.23% 0.23% AddedShares held: Q3 2020 494.2k, Q4 2020 1.2m, Q1 2021 494.2k, Q2 2021 825.9k +331.7k +331,721 67.1%

Sold out since Q1 2021

SecurityTickerShares held beforeValue then
NEVRO CORP NVRO 1.75 06.01.21 NVRO 1.75 06.01.21 115,776,000 $168.4m115.8m shares
BOSTON SCIENTIFIC CORP BSX BSX 2,857,000 $110.4m2.9m shares
ALEXION PHARMACEUTICALS INC ALXN ALXN 579,248 $88.6m579.2k shares
BIOGEN INC BIIB BIIB 310,000 $86.7m310.0k shares
DEERFIELD HEALTHCARE TECH AC 6,778,750 $82.2m6.8m shares
ORTHO CLINICAL DIAGNOSTICS H OCDX OCDX 2,352,941 $45.4m2.4m shares
HILL ROM HLDGS INC HRC HRC 279,870 $30.9m279.9k shares
SOTERA HEALTH CO SHC SHC 1,111,000 $27.7m1.1m shares
GENERATION BIO CO 897,779 $25.6m897.8k shares
MONTES ARCHIMEDES ACQUISITIO 2,000,000 $20.4m2.0m shares
CERTARA INC CERT CERT 600,000 $16.4m600.0k shares
PACIFIC BIOSCIENCES CALIF IN PACB PACB 468,000 $15.6m468.0k shares
RUBIUS THERAPEUTICS INC RUBY RUBY 550,000 $14.6m550.0k shares
STRYKER CORPORATION SYK SYK 59,000 $14.4m59.0k shares
HIGHCAPE CAP ACQUISITION COR 1,000,000 $12.9m1.0m shares
AUTOLUS THERAPEUTICS PLC AUTL AUTL 2,142,857 $12.3m2.1m shares
SIGNIFY HEALTH INC SGFY SGFY 400,000 $11.7m400.0k shares
BOLT BIOTHERAPEUTICS INC 350,000 $11.5m350.0k shares
NEURONETICS INC STIM STIM 919,000 $11.4m919.0k shares
PETCO HEALTH & WELLNESS CO I WOOF WOOF 500,000 $11.1m500.0k shares
INNOVAGE HLDG CORP INNV INNV 300,000 $7.7m300.0k shares
4D MOLECULAR THERAPEUTICS IN FDMT FDMT 150,000 $6.5m150.0k shares
GRACELL BIOTECHNOLOGIES INC 400,000 $6.2m400.0k shares
SENSEI BIOTHERAPEUTICS INC SNSE SNSE 375,000 $5.4m375.0k shares
LANDOS BIOPHARMA INC 450,000 $4.3m450.0k shares

Trades reported as a company insider in Q2 2021

Owning 10% or more of a company, or having someone on its board, makes this manager an insider there: it reports its trades in that company's shares on Form 4 within two business days. Open-market and private purchases and sales only.

DateCompanyTickerTradeShares ValueTheir holding
2021-06-30 LARIMAR THERAPEUTICS INC Director · Through Deerfield Private Design Fund IV, L.P. LRMR Bought 228,571 $2.0m228.6k shares +13%
2021-06-30 LARIMAR THERAPEUTICS INC Director · Through Deerfield Healthcare Innovations Fund, L.P. LRMR Bought 228,570 $2.0m228.6k shares +13%
2021-06-30 LARIMAR THERAPEUTICS INC Director · Through Deerfield Private Design Fund III, L.P. LRMR Bought 228,569 $2.0m228.6k shares +13%
2021-05-04 WEREWOLF THERAPEUTICS INC 10% owner · Through Deerfield Partners, L.P. HOWL Bought 800,000 $12.8m800.0k shares +46%